This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Insider Trading Alert - BSFT, AMBA, GOOG, ADT And NVAX Traded By Insiders

Novavax (NVAX) - FREE Research Report

Phillips Barclay A who is SVP, Chief Financial Officer at Novavax bought 9,868 shares at $2.29 on Feb. 4, 2014. Following this transaction, the SVP, Chief Financial Officer owned 9,868 shares meaning that the stake was reduced by 100% with the 9,868-share transaction.

Glenn Gregory M who is SVP, Research and Development at Novavax bought 4,102 shares at $2.29 on Feb. 4, 2014. Following this transaction, the SVP, Research and Development owned 31,000 shares meaning that the stake was reduced by 15.25% with the 4,102-share transaction.

Wilson Russell P who is SVP, Business Development at Novavax bought 4,900 shares at $2.29 on Feb. 4, 2014. Following this transaction, the SVP, Business Development owned 54,900 shares meaning that the stake was reduced by 9.8% with the 4,900-share transaction.

Erck Stanley C who is President and CEO at Novavax bought 11,868 shares at $2.29 on Feb. 4, 2014. Following this transaction, the President and CEO owned 74,868 shares meaning that the stake was reduced by 18.84% with the 11,868-share transaction.

Hahn Timothy Jon who is SVP, Manufacturing & PD at Novavax bought 9,416 shares at $2.29 on Feb. 4, 2014. Following this transaction, the SVP, Manufacturing & PD owned 80,416 shares meaning that the stake was reduced by 13.26% with the 9,416-share transaction.

The shares most recently traded at $5.21, up $2.92, or 56.05% since the insider transaction. Historical insider transactions for Novavax go as follows:

  • 24-Week # shares bought: 100,000

The average volume for Novavax has been 5.4 million shares per day over the past 30 days. Novavax has a market cap of $1.1 billion and is part of the health care sector and drugs industry. Shares are up 3.52% year-to-date as of the close of trading on Tuesday.

Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. Currently there are 4 analysts that rate Novavax a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NVAX - FREE

TheStreet Quant Ratings rates Novavax as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and weak operating cash flow. Get the full Novavax Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research
5 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs